U.S. FDA allows expanded use of Bristol Myers' cell therapy

2Seventy Bio

05/04/2024 14:09

April 5 (Reuters) - The U.S. Food and drug
Administration on Friday allowed use of Bristol-Myers Squibb
 BMY.N  and 2seventybio's  TSVT.O  cell therapy Abecma in less
severely affected patients with a type of blood cancer. 
    The health regulator is also reviewing another cancer cell
therapy, Carvykti, from Johnson & Johnson  JNJ.N  and its
partner Legend Biotech  LEGN.O  for use in less severely
affected patients. 

 (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing
by Krishna Chandra Eluri)
 ((Sneha.SK@thomsonreuters.com;))